Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Mar 29

PMID 36983417

Authors

Kosuke Ueda

Naoyuki Ogasawara

Naoki Ito

Satoshi Ohnishi

Hiroki Suekane

Hirofumi Kurose

Tasuku Hiroshige

Katsuaki Chikui

Keiichiro Uemura

Kiyoaki Nishihara

Makoto Nakiri

Shigetaka Suekane

Tsukasa Igawa

Affiliations

Soon will be listed here.

Abstract

Nivolumab and ipilimumab (NIVO + IPI) is standard therapy for patients with advanced renal cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in patients with various cancers treated with immune checkpoint inhibitors. Herein, we determined the prognostic value of pretreatment ALC in advanced RCC patients treated with NIVO + IPI as first-line therapy. Data from 46 advanced RCC patients treated with NIVO + IPI between September 2018 and August 2022 were retrospectively reviewed and analyzed. Median progression-free survival (PFS) and overall survival (OS) were significantly shorter in patients with low than high ALC (PFS: = 0.0095; OS: = 0.0182). Multivariate analysis suggested that prior nephrectomy [hazard ratio (HR) = 3.854, 95% confidence interval (CI) = 1.433-10.359, = 0.0075] and pretreatment ALC (HR = 2.513, 95% CI = 1.119-5.648, = 0.0257) were independent factors for PFS. Our new prognostic ALNx model based on ALC and prior nephrectomy suggested that the poor-risk group was a predictor of significantly worse PFS ( < 0.0001) and OS ( = 0.0016). Collectively, the developed ALNx model may be a novel predictor of response in advanced RCC patients treated with NIVO + IPI.

Citing Articles

Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy.

Ueda K, Ito N, Sakai Y, Ohnishi S, Hirano T, Kurose H Int J Clin Oncol. 2025; .

PMID: 39899167 DOI: 10.1007/s10147-025-02710-8.

Polygenic risk score model for renal cell carcinoma in the Korean population and relationship with lifestyle-associated factors.

Hong J, Han J, Jeong S, Kwak C, Kim H, Jeong C BMC Genomics. 2024; 25(1):46.

PMID: 38200428 PMC: 10777500. DOI: 10.1186/s12864-024-09974-w.

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

Tomita Y, Motzer R, Choueiri T, Rini B, Miyake H, Oya M ESMO Open. 2023; 8(6):102034.

PMID: 37866029 PMC: 10774904. DOI: 10.1016/j.esmoop.2023.102034.

References

Zhao Q, Bi Y, Xue J, Liu Y, Zhu J, Qin S . Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis. Ann Transl Med. 2022; 10(13):744. PMC: 9358517. DOI: 10.21037/atm-22-2669. View

Lee K, Kim E, Yun J, Park Y, DO S, Chae S . The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018; 18(1):938. PMC: 6167816. DOI: 10.1186/s12885-018-4832-5. View

Das S, Johnson D . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):306. PMC: 6858629. DOI: 10.1186/s40425-019-0805-8. View

Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K . Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Target Oncol. 2019; 14(4):453-463. DOI: 10.1007/s11523-019-00660-6. View

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen J, Blank C . Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2018; 5(2):164-170. PMC: 6439568. DOI: 10.1001/jamaoncol.2018.5543. View

Ko J, Xie W, Kroeger N, Lee J, Rini B, Knox J . The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015; 16(3):293-300. DOI: 10.1016/S1470-2045(14)71222-7. View

Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T . Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers (Basel). 2022; 14(22). PMC: 9688397. DOI: 10.3390/cancers14225659. View

Templeton A, Knox J, Lin X, Simantov R, Xie W, Lawrence N . Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. Eur Urol. 2016; 70(2):358-64. DOI: 10.1016/j.eururo.2016.02.033. View

Albiges L, Tannir N, Burotto M, McDermott D, Plimack E, Barthelemy P . First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2021; 81(3):266-271. PMC: 10202028. DOI: 10.1016/j.eururo.2021.10.001. View

10.

Ueda K, Suekane S, Kurose H, Ito N, Ogasawara N, Hiroshige T . Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy. Anticancer Res. 2022; 42(9):4573-4580. DOI: 10.21873/anticanres.15960. View

11.

Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M . Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. Ann Surg. 2018; 271(4):693-700. DOI: 10.1097/SLA.0000000000002985. View

12.

Tanaka T, Hatakeyama S, Numakura K, Kido K, Noro D, Oikawa M . Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. Int J Urol. 2020; 27(12):1095-1100. DOI: 10.1111/iju.14363. View

13.

Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W . Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. Int J Clin Oncol. 2022; 27(10):1596-1604. DOI: 10.1007/s10147-022-02215-8. View

14.

Motzer R, Choueiri T, Mcdermott D, Powles T, Vano Y, Gupta S . Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022; 10(3). PMC: 8935174. DOI: 10.1136/jitc-2021-004316. View

15.

Mejean A, Ravaud A, Thezenas S, Colas S, Beauval J, Bensalah K . Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5):417-427. DOI: 10.1056/NEJMoa1803675. View

16.

Rappold P, Vuong L, Leibold J, Chakiryan N, Curry M, Kuo F . A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022; 12(10):2308-2329. PMC: 9720541. DOI: 10.1158/2159-8290.CD-21-0925. View

17.

Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K . Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J Clin Med. 2021; 10(22). PMC: 8617687. DOI: 10.3390/jcm10225325. View

18.

Ernst M, Navani V, Wells J, Donskov F, Basappa N, Labaki C . Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023; 84(1):109-116. DOI: 10.1016/j.eururo.2023.01.001. View

19.

Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M . Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2017; 22(6):1081-1086. DOI: 10.1007/s10147-017-1166-2. View

20.

Cho Y, Park S, Byun H, Lee C, Cho J, Hong M . Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019; 105(5):1065-1073. DOI: 10.1016/j.ijrobp.2019.08.047. View